I-Mab Stock Price, News & Analysis

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, has announced the pricing of an underwritten offering of 33,333,334 American Depositary Shares (ADSs) at $1.95 per ADS, aiming to raise approximately $65 million in gross proceeds.

The offering, expected to close on August 5, 2025, includes participation from notable investors such as Everest Medicines, Janus Henderson Investors, Adage Capital Partners LP, and Exome Asset Management. The proceeds will primarily fund the clinical development of pipeline products, including a randomized Phase 2 trial of givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, targeting progression-free survival data by end of 2027.

I-Mab (NASDAQ: IMAB) has announced the acquisition of Bridge Health Biotech in a strategic move to strengthen its intellectual property portfolio for givastomig, a CLDN18.2 x 4-1BB bispecific antibody. The transaction provides I-Mab with rights to bispecific and multi-specific applications of the CLDN18.2 parental antibody.

The deal includes an upfront payment of $1.8 million, non-contingent payments of $1.2 million through 2027, and potential milestone payments up to $3.875 million. The acquisition eliminates future royalty obligations and reduces milestone payments for givastomig.

Recent Phase 1b dose escalation data showed promising results with an 83% objective response rate in selected doses for expansion cohorts. The company expects to present topline results from the Phase 1b dose expansion combination study in Q1 2026.

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents for cancer treatment, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The company's management will engage in a fireside chat and one-on-one meetings on Tuesday, July 29, 2025, at 10:00 AM ET.

The presentation will be available via webcast on I-Mab's website under the News & Events section, remaining accessible for 90 days following the event.

I-Mab (NASDAQ: IMAB) presented positive Phase 1b dose escalation data for givastomig in combination with nivolumab and mFOLFOX6 at ESMO GI 2025. The study evaluated first-line therapy in Claudin 18.2-positive gastric cancer patients.

Key highlights include a confirmed objective response rate (ORR) of 83% (10/12) at selected doses (8 mg/kg and 12 mg/kg) for the ongoing expansion study. The trial demonstrated efficacy across PD-L1 and CLDN18.2 expression levels, with responses in low-expression tumors. With a median follow-up of 9.0 months, the treatment showed favorable tolerability with minimal Grade 3 adverse events.

The study enrolled 17 U.S. patients across three dose levels (5, 8, and 12 mg/kg), achieving a 71% ORR across all doses and a 100% disease control rate. The longest treatment duration was 13.3 months, with 8 patients remaining on treatment at data cutoff.

I-Mab (NASDAQ: IMAB) announced the publication of promising clinical data for givastomig, their bispecific Claudin 18.2 x 4-1BB antibody, in Clinical Cancer Research. The Phase 1 monotherapy study demonstrated an objective response rate (ORR) of 18% in heavily pretreated Claudin 18.2-positive gastric cancer patients.

Key findings from the 75-patient study include:

• 7 confirmed partial responses in 43 evaluable patients with CLDN18.2-positive advanced gastric cancer
• Disease control rate (DCR) of 49% (21/43 patients)
• Median duration of response of 9.4 months
• Activity observed across Claudin 18.2 expression levels (11% to 100%)
• No dose-limiting toxicity reported up to 15 mg/kg Q2W and 18 mg/kg Q3W

The company will present additional combination therapy data with nivolumab plus mFOLFOX6 at the upcoming ESMO GI Cancers Congress 2025 on July 2nd in Barcelona.

I-Mab (NASDAQ: IMAB) announced positive Phase 1b dose escalation data for givastomig in combination with immunochemotherapy for first-line gastric cancer treatment. The study demonstrated an impressive 71% objective response rate (ORR) across all dose levels, with an even higher 83% ORR in the selected dose expansion cohorts (8 and 12 mg/kg).

Key highlights include rapid and deepening responses even in tumors with low PD-L1 and CLDN18.2 expression, with a 100% disease control rate across all three dose levels. The treatment showed a favorable safety profile with mostly Grade 1 or 2 adverse events. The study enrolled 17 treatment-naïve metastatic gastric cancer patients in the U.S., with 8 patients still continuing treatment, the longest duration being 11.3 months.

I-Mab (NASDAQ: IMAB) announced a virtual investor webinar scheduled for July 8, 2025, at 2:00pm EDT to discuss new data for givastomig, their Claudin 18.2 x 4-1BB bispecific antibody. The webinar will feature Dr. Samuel J. Klempner from Massachusetts General Hospital reviewing Phase 1b combination dose escalation data presented at ESMO GI 2025. The study evaluates givastomig combined with nivolumab and chemotherapy in first-line treatment for Claudin 18.2-positive metastatic gastric cancers, with data from 17 patients. The original data presentation will occur at ESMO GI on July 2, 2025, at 16:50 CEST. The webinar will include a Q&A session, and a replay will be available on I-Mab's website for 90 days.

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents for cancer treatment, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received notification from Nasdaq on June 11, 2025, confirming that its American Depositary Shares (ADSs) had maintained a minimum closing bid price of $1.00 for at least 10 consecutive business days, meeting the requirement under Nasdaq Listing Rule 5550(a)(2). This compliance was achieved on June 10, 2025, and Nasdaq has confirmed that the matter is closed. I-Mab's ADSs will continue to be listed and traded on the Nasdaq stock exchange.

I-Mab (NASDAQ: IMAB), a U.S.-based biotech company specializing in immuno-oncology, has announced its participation in the H.C. Wainwright virtual "HCW@Home" Series on June 17, 2025. The company's management team will engage in a fireside chat focused on Claudin 18.2 as a therapeutic target for gastric cancers, with particular emphasis on their drug candidate givastomig, a Claudin 18.2 x 4-1BB bispecific antibody. The discussion will feature CEO Sean Fu and CMO Phillip Dennis, moderated by H.C. Wainwright Senior Analyst Andres Maldonado. Notably, givastomig's Phase 1 dose escalation study results in combination with immunochemotherapy have been selected for presentation at the upcoming ESMO GI Cancers Congress on July 2, 2025.